Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Jul 2025 Results presented in an Inventiva Pharma media release.
02 Jul 2025 According to Inventiva Pharma media release, the company announced the publication in Journal of Hepatology Reports, a peer-reviewed, scientific journal, of results from the Phase 2b NATIVE clinical trial.
22 May 2024 According to Inventiva Pharma media release, data from the study will be presented as poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver (EASL) on June 5-8, 2024 in Milan, Italy.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com